Christopher M. Hall
President and Chief Operating Officer

Christopher M. Hall was appointed President and Chief Operating Officer of Veracyte in February 2017. He joined the company in March 2010 as Chief Commercial Officer and in September 2014 was named Chief Operating Officer. During his tenure, Mr. Hall led the development and oversight of Veracyte’s commercial enterprise and operations. This included overseeing the successful launch of the company’s three products, including its market-leading Afirma® Gene Expression Classifier, which is becoming the new standard of care in thyroid cancer diagnosis. Before joining Veracyte, Mr. Hall served as a Senior Vice President of Celera Corporation. Prior to this, Mr. Hall held several executive positions at Berkeley HeartLab (BHL; acquired by Celera in 2007), including Chief Clinical Operations Officer and Vice President, Marketing.

During his time at BHL, Mr. Hall led the commercialization of several proprietary genetic tests, as well as the launch of a new sample collection platform and was instrumental in repositioning the company from a specialty laboratory for advanced lipid blood tests to a cardiovascular disease management company. Mr. Hall has also held management and sales positions with Asimba, Kenan Systems, and Symmetrix. Mr. Hall holds a Bachelor of Arts degree from DePauw University in Greencastle, Indiana and an M.B.A. from Harvard University.